Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
| ▸ | ACHE | P22303 | 1/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.62 |
| ▸ | DRD3 | P35462 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2779272 | 1.00 | SLC7A5 (0.62) | SLC7A5HIF1ACYP3A4ALOX15PTGS1 | |
| SCHEMBL29588290 | 1.00 | SLC7A5 (0.62) | SLC7A5HIF1ACYP3A4ALOX15PTGS1 | |
| Hydrochloric Acid SCHEMBL16816803 | 0.94 | HIF1A (0.56) | SLC7A5HIF1ACYP3A4ALOX15PTGS1 | |
| SCHEMBL8378751 | 0.94 | CYP3A4 (0.56) | SLC7A5HIF1ACYP3A4ALOX15PTGS1 | |
| SCHEMBL8378754 | 0.94 | CYP3A4 (0.56) | SLC7A5HIF1ACYP3A4ALOX15PTGS1 | |
| Hydrochloric Acid SCHEMBL16816807 | 0.94 | HIF1A (0.56) | SLC7A5HIF1ACYP3A4ALOX15PTGS1 | |
| SCHEMBL24947622 | 0.92 | ALDH1A1 (0.58) | SLC7A5HIF1ACYP3A4ALOX15PTGS1 | |
| SCHEMBL27310361 | 0.92 | ALDH1A1 (0.58) | SLC7A5HIF1ACYP3A4ALOX15PTGS1 | |
| SCHEMBL23516382 | 0.89 | CYP3A4 (0.53) | SLC7A5HIF1ACYP3A4ALOX15PTGS1 | |
| SCHEMBL23516383 | 0.89 | CYP3A4 (0.53) | SLC7A5HIF1ACYP3A4ALOX15PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325672-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BICYCLE TX LTD (GB) | 2025-10-23 | — | — | US | claimed |
| EP-4274839-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BicycleTx Limited (GB) | 2023-11-15 | — | — | EP | claimed |
| CN-117062826-A | Antiinfective bicyclic peptide ligands | 拜斯科技术开发有限公司 | 2023-11-14 | — | — | CN | claimed |
| WO-2022148968-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BICYCLETX LIMITED (GB) | 2022-07-14 | — | — | WO | claimed |
| EP-2248901-A1 | Streptogramines and method for preparing same by mutasynthesis | Aventis Pharma S.A. (FR) | 2010-11-10 | — | — | EP | claimed |
| US-20020142947-A1 | STREPTOGRAMINS AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | AVENTIS PHARMA, S.A. | 2002-10-03 | — | — | US | claimed |
| US-6352839-B1 | PREPARING VIRGINIAMYCINS FROM AN ENGINEERED MICROORGANISMS, HAVING THE ABILITY TO PREVENT BIOSYNTHESIS OF THE PRECURSOR ANTIBIOTIC; THE MICROORGANISM IS CULTURED IN THE PRESENCE OF A SECOND PRECURSOR AND THE STREPTOGRAMIN ANALOG IS RECOVERED | AVENTIS PHARMA S.A. (FR) | 2002-03-05 | — | — | US | claimed |
| CN-1152338-A | Streptogramines and method for preparing same by mutasynthesis | RHONE POULENC RORER SA (FR) | 1997-06-18 | — | — | CN | claimed |
| EP-0770132-A1 | STREPTOGRAMINES AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | Aventis Pharma S.A. (FR) | 1997-05-02 | — | — | EP | claimed |
| WO-1996001901-A1 | STREPTOGRAMINES AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | RHONE-POULENC RORER S.A. (FR) | 1996-01-25 | — | — | WO | claimed |
| US-20250325672-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BICYCLE TX LTD (GB) | 2025-10-23 | — | — | US | disclosed |
| US-20240082344-A1 | METHOD OF TREATING PRADER-WILLI SYNDROME | FERRING B.V. (NL) | 2024-03-14 | — | — | US | disclosed |
| US-20230391828-A1 | REGULATORS OF CELL DIVISION | TECHNISCHE UNIVERSITAT DRESDEN (DE) | 2023-12-07 | — | — | US | disclosed |
| EP-3666258-B1 | METHOD OF TREATING PRADER-WILLI SYNDROME | FERRING BV (NL) | 2023-11-15 | — | — | EP | disclosed |
| EP-4274839-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BicycleTx Limited (GB) | 2023-11-15 | — | — | EP | disclosed |
| EP-0770132-A1 | STREPTOGRAMINES AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | Aventis Pharma S.A. (FR) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996004298-A1 | PURIFIED FORM OF STREPTOGRAMINES, PREPARATION OF SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1996-02-15 | — | — | WO | disclosed |
| WO-1996001901-A1 | STREPTOGRAMINES AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | RHONE-POULENC RORER S.A. (FR) | 1996-01-25 | — | — | WO | disclosed |
| EP-0662134-A1 | POLYPEPTIDES INVOLVED IN STREPTOGRAMIN BIOSYNTHESIS, NUCLEOTIDE SEQUENCES CODING FOR SAID POLYPEPTIDES AND USE THEREOF | Aventis Pharma S.A. (FR) | 1995-07-12 | — | — | EP | disclosed |
| WO-1994008014-A1 | POLYPEPTIDES INVOLVED IN STREPTOGRAMIN BIOSYNTHESIS, NUCLEOTIDE SEQUENCES CODING FOR SAID POLYPEPTIDES AND USE THEREOF | RHONE-POULENC RORER S.A. (FR) | 1994-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325672-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | ACE2, SARS1, TMPRSS2 | SLC7A5 2440/4885HIF1A 1897/4885CYP3A4 3012/4885 |
| US-20240082344-A1 | METHOD OF TREATING PRADER-WILLI SYNDROME | OXTR, MC2R, AVPR2 | SLC7A5 2807/4885HIF1A 4673/4885CYP3A4 4763/4885 |
| US-20020142947-A1 | STREPTOGRAMINS AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | EMG1, FBL, SMS | SLC7A5 846/4885HIF1A 1689/4885CYP3A4 2915/4885 |
| US-20230391828-A1 | REGULATORS OF CELL DIVISION | PCNA, BOD1L1, MKI67 | SLC7A5 3835/4885HIF1A 1583/4885CYP3A4 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.